Eradicating the burden of atherosclerotic cardiovascular disease by lowering apolipoprotein b lipoproteins earlier in life

Jennifer G. Robinson; Kevin Jon Williams; Samuel Gidding; Jan Boršen; Ira Tabas; Edward A. Fisher; Chris Packard; Michael Pencina; Zahi A. Fayad; Venkatesh Mani; Kerry Anne Rye; Børge G. Nordestgaard; Anne Tybjærg-Hansen; Pamela S. Douglas; Stephen J. Nicholls; Neha Pagidipati; Allan Sniderman

doi:10.1161/JAHA.118.009778

Eradicating the burden of atherosclerotic cardiovascular disease by lowering apolipoprotein b lipoproteins earlier in life

Jennifer G. Robinson
, Kevin Jon Williams
, Samuel Gidding
, Jan Boršen
, Ira Tabas
, Edward A. Fisher
, Chris Packard
, Michael Pencina
, Zahi A. Fayad
, Venkatesh Mani
, Kerry Anne Rye
, Børge G. Nordestgaard
, Anne Tybjærg-Hansen
, Pamela S. Douglas
, Stephen J. Nicholls
, Neha Pagidipati
, Allan Sniderman

Research output: Contribution to journal › Review article › peer-review

84 Scopus citations

Original language	English
Article number	e009778
Journal	Journal of the American Heart Association
Volume	7
Issue number	20
DOIs	https://doi.org/10.1161/JAHA.118.009778
State	Published - 1 Oct 2018

Keywords

Apolipoprotein
Primary prevention
Randomized trial
Regression

Access to Document

10.1161/JAHA.118.009778

Cite this

Robinson, J. G., Williams, K. J., Gidding, S., Boršen, J., Tabas, I., Fisher, E. A., Packard, C., Pencina, M., Fayad, Z. A., Mani, V., Rye, K. A., Nordestgaard, B. G., Tybjærg-Hansen, A., Douglas, P. S., Nicholls, S. J., Pagidipati, N., & Sniderman, A. (2018). Eradicating the burden of atherosclerotic cardiovascular disease by lowering apolipoprotein b lipoproteins earlier in life. Journal of the American Heart Association, 7(20), Article e009778. https://doi.org/10.1161/JAHA.118.009778

@article{f86029748e8847d68edece7951e5d5b6,

title = "Eradicating the burden of atherosclerotic cardiovascular disease by lowering apolipoprotein b lipoproteins earlier in life",

keywords = "Apolipoprotein, Primary prevention, Randomized trial, Regression",

author = "Robinson, \{Jennifer G.\} and Williams, \{Kevin Jon\} and Samuel Gidding and Jan Bor{\v s}en and Ira Tabas and Fisher, \{Edward A.\} and Chris Packard and Michael Pencina and Fayad, \{Zahi A.\} and Venkatesh Mani and Rye, \{Kerry Anne\} and Nordestgaard, \{B{\o}rge G.\} and Anne Tybj{\ae}rg-Hansen and Douglas, \{Pamela S.\} and Nicholls, \{Stephen J.\} and Neha Pagidipati and Allan Sniderman",

note = "Funding Information: Robinson, MD, MPH has received research grants to Institution: Amarin, Amgen, Astra-Zeneca, Esai, Esperion, Merck, Pfizer, Regeneron, Sanofi, Takeda (all significant) and served as a consultant for Akcea/Ionis, Amgen, Dr Reddy Laboratories, Eli Lilly, Merck, Pfizer (modest) and Regeneron and Sanofi (significant). Bor{\'e}n, MD, PhD has received research grant to Institution: Amgen, Astra-Zeneca, Pfizer, Sanofi/Regeneron and NovoNordisk (all significant), and served as consultant for Eli Lilly, AstraZeneca, MSD, Amgen, NovoNordisk (modest), Zahi Fayad, PhD has received research grants to institution from Amgen, Daiichi Sankyo (all significant). Fisher, MD, PhD has served as an expert witness for Amgen (significant) and is a member of the Merck Speaker{\textquoteright}s Bureau. Gidding, MD has been a consultant for Regenxbio, not significant. Mani, PhD has received grants to institution from Daiichi Sankyo, Novartis and Aegerion (all significant) and is a consultant for Medlion Inc (modest). Nicholls, MD has received institutional grants from AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience and honoraria from AstraZeneca, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion and Boehringer Ingelheim (modest). Nordestgaard, MD, DMSc has served as a consultant or has given talks sponsored by AstraZeneca, Sanofi, Regeneron, Ionis, Amgen, and Kowa (all modest). Packard, MD has received grants from Merck and Sanofi, and honoraria from Merck, Sanofi/Regeneron, Pfizer, Amgen and Daiichi-Sankyo. Pagidipati, MD reports grants to the institution from Sanofi/Regeneron, Alexion, Amgen, Verily, Novartis. Pencina, PhD reports grants to the institution from Sanofi/Regeneron. Rye, PhD acts as a consultant for CSL Limited (modest). Tabas, MD, PhD has served as a consultant for Merck, LipimetiX Development, Inc., and Novartis (modest). Williams, MD has ownership interests in Hygieia, Inc., and Gemphire Therapeutics, Inc. (both significant) and serves on the Medical and Scientific Advisory Board for Gemphire. The remaining authors have no disclosures to report. Funding Information: Gidding is supported by the Coronary Artery Risk Development in Young Adults Study (CARDIA) (contracts HHSN-268201300025C, HHSN268201300026C, HHSN26820130-0027C, HHSN268201300028C, HHSN268201300029C, and HHSN268200900041C from the National Heart, Lung, and Blood Institute [NHLBI], the Intramural Research Program of the National Institute on Aging [NIA], and an intra-agency agreement between NIA and NHLBI AG0005]). Tabas is supported by grants HL075662, HL132412, HL140554, and HL127464 from the National Heart, Lung, and Blood Institute (NHLBI). Fisher is supported by NIH grants HL 084312, 131481, 129433, and DoD grant 12019098. Fayad is supported by grants P01HL131478, 1R01HL128056, 2R01HL070121, R01EB009638, R01HL119828, R01HL-118440, R01HL125703, 1U01AR068043, R01HL135878, R01HL127637, R01HL135093 and R01AR068425 from the NIH and 14SFRN20780005 from the American Heart Association. Mani is supported by P01HL131478, 1R01HL128056, 2R01HL070121, 1U01AR068043, R01HL127637 from the NIH and 14SFRN20780005, 17GRNT33420119 from the American Heart Association. Rye has received support from the National Health and Medical Research Council of Australia APP1037903.",

year = "2018",

month = oct,

day = "1",

doi = "10.1161/JAHA.118.009778",

language = "English",

volume = "7",

journal = "Journal of the American Heart Association",

issn = "2047-9980",

publisher = "American Heart Association Inc.",

number = "20",

}

Robinson, JG, Williams, KJ, Gidding, S, Boršen, J, Tabas, I, Fisher, EA, Packard, C, Pencina, M, Fayad, ZA , Mani, V, Rye, KA, Nordestgaard, BG, Tybjærg-Hansen, A, Douglas, PS, Nicholls, SJ, Pagidipati, N & Sniderman, A 2018, 'Eradicating the burden of atherosclerotic cardiovascular disease by lowering apolipoprotein b lipoproteins earlier in life', Journal of the American Heart Association, vol. 7, no. 20, e009778. https://doi.org/10.1161/JAHA.118.009778

TY - JOUR

T1 - Eradicating the burden of atherosclerotic cardiovascular disease by lowering apolipoprotein b lipoproteins earlier in life

AU - Robinson, Jennifer G.

AU - Williams, Kevin Jon

AU - Gidding, Samuel

AU - Boršen, Jan

AU - Tabas, Ira

AU - Fisher, Edward A.

AU - Packard, Chris

AU - Pencina, Michael

AU - Fayad, Zahi A.

AU - Mani, Venkatesh

AU - Rye, Kerry Anne

AU - Nordestgaard, Børge G.

AU - Tybjærg-Hansen, Anne

AU - Douglas, Pamela S.

AU - Nicholls, Stephen J.

AU - Pagidipati, Neha

AU - Sniderman, Allan

N1 - Funding Information: Robinson, MD, MPH has received research grants to Institution: Amarin, Amgen, Astra-Zeneca, Esai, Esperion, Merck, Pfizer, Regeneron, Sanofi, Takeda (all significant) and served as a consultant for Akcea/Ionis, Amgen, Dr Reddy Laboratories, Eli Lilly, Merck, Pfizer (modest) and Regeneron and Sanofi (significant). Borén, MD, PhD has received research grant to Institution: Amgen, Astra-Zeneca, Pfizer, Sanofi/Regeneron and NovoNordisk (all significant), and served as consultant for Eli Lilly, AstraZeneca, MSD, Amgen, NovoNordisk (modest), Zahi Fayad, PhD has received research grants to institution from Amgen, Daiichi Sankyo (all significant). Fisher, MD, PhD has served as an expert witness for Amgen (significant) and is a member of the Merck Speaker’s Bureau. Gidding, MD has been a consultant for Regenxbio, not significant. Mani, PhD has received grants to institution from Daiichi Sankyo, Novartis and Aegerion (all significant) and is a consultant for Medlion Inc (modest). Nicholls, MD has received institutional grants from AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience and honoraria from AstraZeneca, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion and Boehringer Ingelheim (modest). Nordestgaard, MD, DMSc has served as a consultant or has given talks sponsored by AstraZeneca, Sanofi, Regeneron, Ionis, Amgen, and Kowa (all modest). Packard, MD has received grants from Merck and Sanofi, and honoraria from Merck, Sanofi/Regeneron, Pfizer, Amgen and Daiichi-Sankyo. Pagidipati, MD reports grants to the institution from Sanofi/Regeneron, Alexion, Amgen, Verily, Novartis. Pencina, PhD reports grants to the institution from Sanofi/Regeneron. Rye, PhD acts as a consultant for CSL Limited (modest). Tabas, MD, PhD has served as a consultant for Merck, LipimetiX Development, Inc., and Novartis (modest). Williams, MD has ownership interests in Hygieia, Inc., and Gemphire Therapeutics, Inc. (both significant) and serves on the Medical and Scientific Advisory Board for Gemphire. The remaining authors have no disclosures to report. Funding Information: Gidding is supported by the Coronary Artery Risk Development in Young Adults Study (CARDIA) (contracts HHSN-268201300025C, HHSN268201300026C, HHSN26820130-0027C, HHSN268201300028C, HHSN268201300029C, and HHSN268200900041C from the National Heart, Lung, and Blood Institute [NHLBI], the Intramural Research Program of the National Institute on Aging [NIA], and an intra-agency agreement between NIA and NHLBI AG0005]). Tabas is supported by grants HL075662, HL132412, HL140554, and HL127464 from the National Heart, Lung, and Blood Institute (NHLBI). Fisher is supported by NIH grants HL 084312, 131481, 129433, and DoD grant 12019098. Fayad is supported by grants P01HL131478, 1R01HL128056, 2R01HL070121, R01EB009638, R01HL119828, R01HL-118440, R01HL125703, 1U01AR068043, R01HL135878, R01HL127637, R01HL135093 and R01AR068425 from the NIH and 14SFRN20780005 from the American Heart Association. Mani is supported by P01HL131478, 1R01HL128056, 2R01HL070121, 1U01AR068043, R01HL127637 from the NIH and 14SFRN20780005, 17GRNT33420119 from the American Heart Association. Rye has received support from the National Health and Medical Research Council of Australia APP1037903.

PY - 2018/10/1

Y1 - 2018/10/1

KW - Apolipoprotein

KW - Primary prevention

KW - Randomized trial

KW - Regression

UR - https://www.scopus.com/pages/publications/85055616825

U2 - 10.1161/JAHA.118.009778

DO - 10.1161/JAHA.118.009778

M3 - Review article

C2 - 30371276

AN - SCOPUS:85055616825

SN - 2047-9980

VL - 7

JO - Journal of the American Heart Association

JF - Journal of the American Heart Association

IS - 20

M1 - e009778

ER -